1. Home
  2. PAYO vs LQDA Comparison

PAYO vs LQDA Comparison

Compare PAYO & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PAYO
  • LQDA
  • Stock Information
  • Founded
  • PAYO 2005
  • LQDA 2004
  • Country
  • PAYO United States
  • LQDA United States
  • Employees
  • PAYO N/A
  • LQDA N/A
  • Industry
  • PAYO EDP Services
  • LQDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • PAYO Technology
  • LQDA Health Care
  • Exchange
  • PAYO Nasdaq
  • LQDA Nasdaq
  • Market Cap
  • PAYO 2.1B
  • LQDA 1.9B
  • IPO Year
  • PAYO N/A
  • LQDA 2018
  • Fundamental
  • Price
  • PAYO $5.70
  • LQDA $23.05
  • Analyst Decision
  • PAYO Strong Buy
  • LQDA Strong Buy
  • Analyst Count
  • PAYO 8
  • LQDA 9
  • Target Price
  • PAYO $10.06
  • LQDA $32.67
  • AVG Volume (30 Days)
  • PAYO 2.9M
  • LQDA 3.0M
  • Earning Date
  • PAYO 11-04-2025
  • LQDA 11-12-2025
  • Dividend Yield
  • PAYO N/A
  • LQDA N/A
  • EPS Growth
  • PAYO N/A
  • LQDA N/A
  • EPS
  • PAYO 0.25
  • LQDA N/A
  • Revenue
  • PAYO $1,017,244,000.00
  • LQDA $19,322,000.00
  • Revenue This Year
  • PAYO $9.34
  • LQDA $405.58
  • Revenue Next Year
  • PAYO $7.48
  • LQDA $373.93
  • P/E Ratio
  • PAYO $23.55
  • LQDA N/A
  • Revenue Growth
  • PAYO 13.02
  • LQDA 30.20
  • 52 Week Low
  • PAYO $5.69
  • LQDA $9.71
  • 52 Week High
  • PAYO $11.29
  • LQDA $29.94
  • Technical
  • Relative Strength Index (RSI)
  • PAYO 30.98
  • LQDA 46.02
  • Support Level
  • PAYO $5.69
  • LQDA $22.39
  • Resistance Level
  • PAYO $6.01
  • LQDA $24.46
  • Average True Range (ATR)
  • PAYO 0.22
  • LQDA 1.21
  • MACD
  • PAYO -0.03
  • LQDA 0.06
  • Stochastic Oscillator
  • PAYO 1.43
  • LQDA 45.09

About PAYO Payoneer Global Inc.

Payoneer Global Inc is a financial technology company purpose-built to enable the world's small and medium-sized businesses (SMB(s)) to grow and operate their businesses around the world by reliably and securely connecting them to the digital economy. The company started to empower commerce by connecting businesses, professionals, countries, and currencies with its diversified cross-border payments platform.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Share on Social Networks: